Posted Jun. 3, 2013 at 6:45 a.m.

Premium Lock GSK kidney cancer drug shows promise against ovarian cancer

Published: 2013-06-03 06:45:41
Updated: 2013-06-03 06:45:41

Cancer research  Cancer research

Disease progression was delayed for a median of 17.9 months among patients taking Votrient, compared with 12.3 months among those on placebo, according to the study of 940 patients with advanced ovarian, fallopian tube and primary peritoneal cancer, GSK says....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders